Entendiendo las terapias actuales en melanoma metastásico / Understanding current therapies in metastatic melanoma
Rev. méd. Chile
;
144(11): 1448-1458, nov. 2016. ilus, tab
Artículo
en Español
| LILACS
| ID: biblio-845467
ABSTRACT
Cutaneous melanoma is a highly aggressive tumor developing from melanocytes, its incidence is increasing, and prognosis in advanced stages is daunting. New therapies have been approved during the recent years with unprecedented results, including inhibitors of MAPK/ERK pathway and immune checkpoint blockade (anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) as ipilimumab, anti-programmed cell death protein 1 (PD-L1) as pembrolizumab and anti-programmed cell death protein 1 ligand (PD-L1), among many others). The aim of this paper is to review currently available metastatic melanoma therapies focusing mainly on new therapies that have demonstrated effectiveness, after several decades of little progress in the treatment of this disease.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Neoplasias Cutáneas
/
Melanoma
/
Antineoplásicos
Límite:
Humanos
Idioma:
Español
Revista:
Rev. méd. Chile
Asunto de la revista:
Medicina
Año:
2016
Tipo del documento:
Artículo
País de afiliación:
Chile
Institución/País de afiliación:
Pontificia Universidad Católica de Chile/CL
Similares
MEDLINE
...
LILACS
LIS